CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 25,000 shares at an average $64.88 ($1,621,894)
- 4 Shares withheld for taxes Chief Medical Officer gave up 2,527 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 25,000 shares at an average $50.67 ($1,266,638)
- 4 Open-market sale Chief Executive Officer sold 25,000 shares at an average $44.46 ($1,111,504)
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Executive Officer gave up 9,444 shares (to pay taxes)
- 4 Shares withheld for taxes General Counsel and Secretary gave up 2,305 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 25,000 shares at an average $48.25 ($1,206,243)
- 4 Shares withheld for taxes Chief Financial Officer gave up 1,392 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 6,373 shares (to pay taxes)
- 4 Shares withheld for taxes General Counsel and Secretary gave up 1,950 shares (to pay taxes)
- 4 Open-market sale Chief Executive Officer sold 25,000 shares at an average $51.47 ($1,286,798)
- 4 Open-market sale Chief Executive Officer sold 25,000 shares at an average $40.93 ($1,023,290)
- 4 Option exercise Chief Executive Officer acquired 58,233 shares (option exercise)
Page 8 of 26 · 502 filings